The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporin. (PubMed, Front Nephrol) - Apr 1, 2025 - P3 | "Samples were analyzed from a cohort of patients in AURORA 1 treated with voclosporin (23.7 mg twice daily, n=57) or placebo (n=59) in combination with mycophenolate mofetil (MMF) and low-dose glucocorticoids, including in a subgroup of patients that experienced a ≥30% decline from baseline in estimated glomerular filtration rate (voclosporin, n=26; placebo, n=20). These findings further support the safety of voclosporin for the treatment of LN in adult patients. ClinicalTrials.gov , identifier NCT03021499; EudraCT, identifier 2016-004045-81."
Biomarker • Journal • Fibrosis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • KIM1 • TGFB1
|
|
Biff F Palmer; Jai Radhakrishnan; James A Tumlin; Jennifer L Cross; Linda M Rehaume; Robert B Huizinga
|